Our results warrant future clinical and mechanistic studies to determine whether dMMR/MSI GALNT7-Low colorectal cancers derive greater benefit from PD-1/PD-L1 blockade, alone or in combination with a CTLA-4, TIM-3, or LAG-3 inhibitor. This evidence concerns the gene LAG3 and colorectal cancer.